<DOC>
	<DOC>NCT01847014</DOC>
	<brief_summary>SYMPHONY Extension is an extension of AC-055-401, a multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with Pulmonary Arterial Hypertension to psychometrically validate the PAH-SYMPACT instrument. The objective is to assess the long-term safety of macitentan in subjects with PAH beyond the treatment in the AC-055-401 study.</brief_summary>
	<brief_title>Clinical Study of Macitentan in Patients With PAH to Psychometrically Validate PAH-SYMPACT Instrument</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>Signed informed consent prior to any studymandated procedure. Patients with PAH who completed study AC055401 Women of childbearing potential must: Have a negative urine pregnancy test at Visit 1 and agree to perform monthly serum pregnancy tests. Agree to use two methods of contraception from Visit 1 until 1 month after study drug discontinuation. Patients who prematurely discontinued study drug in study AC055401 Females who are lactating or pregnant (positive Visit 1 pregnancy test) or plan to become pregnant during the study Known hypersensitivity to macitentan or its excipients or drugs of the same class</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Pulmonary Arterial Hypertension (PAH)</keyword>
	<keyword>psychometric instrument</keyword>
	<keyword>PAH-SYMPACT</keyword>
</DOC>